Pancreatic lipase: why laboratory community does not take enough care of this clinically important test?
| Autor: | Pasqualetti S; Research Centre for Metrological Traceability in Laboratory Medicine (CIRME), University of Milan, Milan, Italy.; Clinical Pathology Unit, Luigi Sacco University Hospital, via GB Grassi 74, Milan, 20157, Italy., Borrillo F; Research Centre for Metrological Traceability in Laboratory Medicine (CIRME), University of Milan, Milan, Italy., Rovegno L; Research Centre for Metrological Traceability in Laboratory Medicine (CIRME), University of Milan, Milan, Italy., Panteghini M; Research Centre for Metrological Traceability in Laboratory Medicine (CIRME), University of Milan, Milan, Italy. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinical chemistry and laboratory medicine [Clin Chem Lab Med] 2021 Sep 17; Vol. 59 (12), pp. 1914-1920. Date of Electronic Publication: 2021 Sep 17 (Print Publication: 2021). |
| DOI: | 10.1515/cclm-2021-0850 |
| Abstrakt: | Although being the recommended laboratory test to diagnose acute pancreatitis, serum pancreatic lipase (LIP) is among the poorly standardized laboratory tests, and laboratory stakeholders often appear to not take enough care of the quality of its measurements. Here we discuss some important issues that, if not correctly managed and solved, make misdiagnosis of acute pancreatitis by using serum LIP a real possibility. First, the current unavailability of a suitable higher-order reference material to be used as common calibrator should be filled up to definitively improve the inter-method bias. Second, knowledge of the analytical characteristics that may explain the defective performance of LIP assays should be deepened. IVD manufacturers should be more explicit in providing this information, including description of their internal protocol for transferring LIP values from internal references to commercial calibrators. Third, recommended models for accurately estimating measurement uncertainty and reliably defining analytical performance specifications for LIP measurements should be applied. Finally, investments considering alternative options for measuring LIP (e.g., targeted to the development of automated LIP immunoassays) should be warranted. All involved stakeholders (standardization bodies, higher-order reference providers, in vitro diagnostics manufacturers, and laboratory professionals) should contribute to fill the existing gap. (© 2021 Walter de Gruyter GmbH, Berlin/Boston.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|